Torray Investment Partners LLC Has $15.67 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Torray Investment Partners LLC increased its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 394.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 60,127 shares of the medical research company's stock after buying an additional 47,969 shares during the quarter. Amgen comprises 2.2% of Torray Investment Partners LLC's portfolio, making the stock its 14th largest position. Torray Investment Partners LLC's holdings in Amgen were worth $15,672,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of AMGN. Capital Performance Advisors LLP acquired a new stake in shares of Amgen in the third quarter valued at about $25,000. Centricity Wealth Management LLC acquired a new stake in shares of Amgen in the fourth quarter valued at about $25,000. Legacy Investment Solutions LLC acquired a new stake in shares of Amgen in the third quarter valued at about $29,000. Synergy Investment Management LLC acquired a new stake in shares of Amgen in the fourth quarter valued at about $34,000. Finally, Heck Capital Advisors LLC acquired a new stake in shares of Amgen in the fourth quarter valued at about $36,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the company's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Jonathan P. Graham sold 25,045 shares of the company's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $293.12, for a total value of $7,341,190.40. Following the sale, the executive vice president now owns 28,987 shares of the company's stock, valued at approximately $8,496,669.44. This trade represents a 46.35 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 69,341 shares of company stock worth $20,644,335 over the last 90 days. 0.69% of the stock is currently owned by corporate insiders.

Amgen Stock Up 0.5 %

NASDAQ:AMGN traded up $1.41 during trading hours on Tuesday, hitting $312.19. 3,819,193 shares of the company's stock traded hands, compared to its average volume of 2,546,395. The firm has a market cap of $167.71 billion, a P/E ratio of 41.35, a P/E/G ratio of 2.63 and a beta of 0.56. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The stock's fifty day moving average price is $282.76 and its two-hundred day moving average price is $299.66.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.05%. Amgen's dividend payout ratio (DPR) is currently 126.09%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on AMGN. Jefferies Financial Group restated a "buy" rating and set a $380.00 price objective on shares of Amgen in a research note on Tuesday, November 12th. William Blair reiterated an "outperform" rating on shares of Amgen in a research report on Tuesday, November 12th. UBS Group reiterated a "hold" rating on shares of Amgen in a research report on Wednesday, February 12th. StockNews.com lowered Amgen from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. Finally, Wells Fargo & Company restated an "equal weight" rating on shares of Amgen in a research report on Wednesday, February 5th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $314.09.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.